Ⅱ
General Information
DRACP ID DRACP01180
Peptide Name Ⅱ
Sequence XPAXXFXPAXXLXXLXXLX
Sequence Length 19
UniProt ID Not available
PubChem CID Not available
Origin Peptaibols
Type Native peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
HCT 8 | Colon adenocarcinoma | Carcinoma | IC50=5.93 μM | MTT assay | 3-5 days | Patent |
BEL-7402 | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=1.94 μM | MTT assay | 3-5 days | Patent |
BGC-823 | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=1.03 μM | MTT assay | 3-5 days | Patent |
A549 | Lung adenocarcinoma | Carcinoma | IC50=2.08 μM | MTT assay | 3-5 days | Patent |
A2780 | Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary | Carcinoma | IC50=3.79 μM | MTT assay | 3-5 days | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Acetylation
C-terminal Modification Aminoethanol
Other Modification X(1/4/5/17)=Aib=1-amino-isobutyric acid; X(7/13/16)=Iva=Isovaline; X(10)=AHMA=3-amino-2-hydroxy-3-methylbutanoic acid; X(11/14/19)(β)A=β-Alanine
Chiral L
Physicochemical Information
Formula C43H46N8O-2
Absent amino acids CDEGHIKMNQRSTVWY
Common amino acids X
Mass 217413
Pl 6.11
Basic residues 0
Acidic residues 0
Hydrophobic residues 6
Net charge 0
Boman Index 2136
Hydrophobicity 76.84
Aliphatic Index 72.11
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available